IDEAYA Biosciences (NASDAQ:IDYA) – Investment analysts at Oppenheimer lifted their FY2019 earnings per share (EPS) estimates for shares of IDEAYA Biosciences in a research report issued to clients and investors on Wednesday, November 13th. Oppenheimer analyst K. Degeeter now expects that the company will post earnings per share of ($2.62) for the year, up from their previous estimate of ($2.79). Oppenheimer currently has a “Outperform” rating and a $17.00 target price on the stock. Oppenheimer also issued estimates for IDEAYA Biosciences’ Q1 2020 earnings at ($0.73) EPS, Q2 2020 earnings at ($0.78) EPS, Q3 2020 earnings at ($0.82) EPS, Q4 2020 earnings at ($0.86) EPS and FY2020 earnings at ($3.19) EPS.
IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Wednesday, November 13th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.12.
Shares of IDYA stock opened at $7.81 on Friday. IDEAYA Biosciences has a 52 week low of $4.89 and a 52 week high of $16.90. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.95 and a current ratio of 18.94. The business has a fifty day moving average of $6.78.
A number of hedge funds have recently made changes to their positions in IDYA. Perceptive Advisors LLC purchased a new stake in IDEAYA Biosciences in the 2nd quarter worth $11,369,000. Boxer Capital LLC purchased a new stake in IDEAYA Biosciences in the 2nd quarter worth $7,612,000. Point72 Asset Management L.P. purchased a new stake in IDEAYA Biosciences in the 2nd quarter worth $1,948,000. Victory Capital Management Inc. purchased a new stake in IDEAYA Biosciences in the 2nd quarter worth $1,453,000. Finally, Monashee Investment Management LLC purchased a new stake in IDEAYA Biosciences in the 2nd quarter worth $354,000. Institutional investors and hedge funds own 24.84% of the company’s stock.
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
See Also: What is the Quick Ratio?
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.